CStone announces positive sugemalimab data publication in JAMA

CStone Pharmaceuticals (HKEX: 2616) announced the publication of positive results from its GEMSTONE-303 study in JAMA, highlighting the efficacy of sugemalimab (Cejemly®) in treating advanced gastric cancer. The study demonstrated that sugemalimab, in combination with chemotherapy, significantly improved overall survival (OS) and progression-free survival (PFS) in patients with PD-L1 CPS ≥ 5. Median OS increased to 15.6 months compared to 12.6 months in the control group, reducing the risk of death by 25%. Median PFS also improved to 7.6 months versus 6.1 months. The drug has been approved for five indications in China, and for first-line lung cancer treatment in Europe and the UK. CStone aims to further expand global registration and commercialization.